The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...

If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as ...

Goldman Sachs’ Scott Rubner predicts a year-end rally that will push the S&P to 6,200 points as reported by Bloomberg on ...

US healthcare giant Johnson & Johnson has filed a supplemental Biologics License Application with the US Food and Drug ...

Johnson & Johnson seeks US FDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis: Spring House, Pennsylvania Monday, November 25, 2024, 11:00 Hrs [IST] ...

Johnson & Johnson announced the submission of a supplemental Biologics License Application to the U.S. FDA seeking approval of a ...

Johnson & Johnson (J&J) Innovation Medicine has submitted a request to the US Food and Drug Administration (FDA) to approve a new way of starting treatment with its drug Tremfya (guselkumab ...

This comes after the FDA approved TREMFYA® for the same condition in September 2024, which was administered via an intravenous (IV) induction regimen followed by a SC maintenance regimen.

Johnson & Johnson (JNJ) announced the submission of a supplemental Biologics License Application to the FDA seeking approval of a ...